All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Itacitinib and corticosteroids for chronic GvHD
Featured
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Annie Im, University of Pittsburgh, Pittsburgh, US. We asked about itacitinib and corticosteroids for chronic graft-versus-host disease.
Itacitinib and corticosteroids for chronic GvHD
Im opens by discussing steroid treatment, which remains the standard of care, and the need for improved therapied based on disease outcomes. Im goes on to outline itacitinib, a JAK1 inhibitor, as a potential new treatment which could be used either alone or in combination with steroids. Im then discusses results from the GRAVITAS-309 trial, including the overall response and adverse events. Finally, Im summarizes the study conclusions on the future of combination treatments involving itacitinib and corticosteroids.
Your opinion matters
20 votes - 43 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox